Skip to main content

Caris Life Sciences, Inc. (CAI) Stock

Caris Life Sciences, Inc. Stock Details, Movements and Public Alerts

Stock Details

Caris Life Sciences, Inc. (CAI), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $25.50. Over the past 52 weeks, it has ranged between $14.19 and $35.20. This places the current price at 72.4% of its 52-week high and 79.7% above its 52-week low. Recent trading volume was recorded at 2,663,244. The 14-day Relative Strength Index (RSI) stands at 60.98, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $19.98 by 27.63%. Similarly, it is above its 200-day moving average of $20.95 by 21.72%. The MACD histogram is -0.24, indicating bearish momentum (MACD Line: 1.70, Signal Line: 1.94). There is currently 1 active alert set for CAI by users.

52-Week Range

$35.20 - $14.19

-27.56% from high · +79.70% from low

Avg Daily Volume

5,304,769

20-day average

100-day avg: 3,686,807

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

2.62

Below market average

Forward P/E

66.35

Earnings expected to decline

Price to Book

11.97

EV/EBITDA

38.75

EPS (TTM)

$9.58

Price to Sales

7.16

Q:How is CAI valued relative to its earnings and growth?
Caris Life Sciences, Inc. trades at a P/E ratio of 2.62, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 66.35 is higher than the current P/E, indicating analysts expect earnings to decline over the next year.
Q:What is CAI's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

10.62%

Operating Margin

10.21%

EBITDA

$174.02M

Return on Equity

20.13%

Return on Assets

8.77%

Revenue Growth (YoY)

45.40%

Q:How profitable and efficient is CAI's business model?
Caris Life Sciences, Inc. achieves a profit margin of 10.62%, meaning it retains $10.62 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 10.21% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 20.13% and ROA at 8.77%, the company generates strong returns on invested capital.
Q:What are CAI's recent growth trends?
Caris Life Sciences, Inc.'s revenue grew by 45.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$7.1B

Revenue (TTM)

$989.60M

Revenue/Share (TTM)

$3.49

Shares Outstanding

282.68M

Book Value/Share

$2.09

Asset Type

EQUITY

Q:What is CAI's market capitalization and position?
Caris Life Sciences, Inc. has a market capitalization of $7.1B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 282.68M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does CAI's price compare to its book value?
Caris Life Sciences, Inc.'s book value per share is $2.09, while the current stock price is $25.50, resulting in a price-to-book (P/B) ratio of 12.18. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$27.50

7.84% upside potential

Analyst Recommendations

Strong Buy

1

Buy

7

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for CAI?
9 analysts cover CAI with 89% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $27.50 implies 7.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on CAI?
Current analyst recommendations:1 Strong Buy, 7 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 8, 2026, 02:20 AM

Technical Indicators

RSI (14-day)

60.98

Neutral

50-Day Moving Average

$19.98

27.63% above MA-50

200-Day Moving Average

$20.95

21.72% above MA-200

MACD Line

1.70

MACD Signal

1.94

MACD Histogram

-0.24

Bearish

Q:What does CAI's RSI value tell investors?
The RSI (Relative Strength Index) for CAI is currently 60.98, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret CAI's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.70 below the signal line at 1.94, with histogram at -0.24. This bearish crossover indicates downward pressure. The 50-day MA ($19.98) is below the 200-day MA ($20.95), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Sep 8, 2026, 12:31 PM

Active Alerts

Alert Condition
Price falls below
Threshold
$14.00
Created
Nov 21, 2025, 03:03 PM

Stay Ahead of the Market with Caris Life Sciences, Inc. Alerts

Set up price alerts for Caris Life Sciences, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.